Haleon plc (HLNCF)
Haleon plc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Weybridge, SU, GB. The stock last traded at $4.86, down 0.51% on the session, giving a market capitalisation of $42.80B. On trailing twelve-month figures it carries a trailing P/E of 19.75, a net margin of 14.6%. Its beta of 0.24 implies it has historically moved less than the broad market.
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.
Haleon plc is most often compared with the following Healthcare names: